Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study

Kobayashi, Tomoko, Iwama, Shintaro, Yasuda, Yoshinori, Okada, Norio, Tsunekawa, Taku, Onoue, Takeshi, Takagi, Hiroshi, Hagiwara, Daisuke +16 more·2018·Journal of the Endocrine Society
DOI 10.1210/js.2017-00432

Cited by (203)

Items 201–203 of 203

  1. Emerging mechanisms and targetable pathways in immune checkpoint inhibitor‑associated thyroid dysfunction: From pathogenesis to potential intervention
    Tianying Zhang, Hengtong Han, Hao Shi, Minghua Ma, Yating Zhang, Tingting Zhang, Libin Ma, Ze Yang, Yong-xun Zhao · 2026 · Critical Reviews in Oncology/Hematology
  2. Real-world insights into incidence and risk factors of thyroid dysfunction following immune checkpoint inhibitor therapy
    Lingyan Zhou, Qinran Long, Ying Zhang, Mei Zhan · 2026 · Frontiers in Immunology
  3. Towards Predicting Immune-Related Adverse Events: Emerging Biomarkers in Patients Undergoing Immune Checkpoint Inhibitor Therapy
    Nežka Hribernik, Martina Reberšek · 2026 · Cancers